IMMUNOTHERAPY Benefit with anti-PD-L1

被引：2
|
作者：
Romero, Diana
机构：
来源：
NATURE REVIEWS CLINICAL ONCOLOGY | 2017年 / 14卷 / 02期
关键词：
D O I：
10.1038/nrclinonc.2016.218
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：70 / 70
页数：1
相关论文
共 50 条
  • [21] FcγR interaction is not required for effective anti-PD-L1 immunotherapy but can add additional benefit depending on the tumor model
    Sow, Heng Sheng
    Benonisson, Hreinn
    Breukel, Cor
    Visser, Remco
    Verhagen, Onno J. H. M.
    Bentlage, Arthur E. H.
    Brouwers, Conny
    Claassens, Jill W. C.
    Linssen, Margot M.
    Camps, Marcel
    van Hall, Thorbald
    Ossendorp, Ferry
    Fransen, Marieke F.
    Vidarsson, Gestur
    Verbeek, J. Sjef
    INTERNATIONAL JOURNAL OF CANCER, 2019, 144 (02) : 345 - 354
  • [22] Phospho-STAT1 expression as a potential biomarker for anti-PD-1/anti-PD-L1 immunotherapy for breast cancer
    Nakayama, Yuko
    Mimura, Kosaku
    Tamaki, Tomoaki
    Shiraishi, Kensuke
    Kua, Ley-Fang
    Koh, Vivien
    Ohmori, Masato
    Kimura, Ayako
    Inoue, Shingo
    Okayama, Hirokazu
    Suzuki, Yoshiyuki
    Nakazawa, Tadao
    Ichikawa, Daisuke
    Kono, Koji
    INTERNATIONAL JOURNAL OF ONCOLOGY, 2019, 54 (06) : 2030 - 2038
  • [23] Enhancing immunotherapy through PD-L1 upregulation: the promising combination of anti-PD-L1 plus mTOR inhibitors
    Hernandez-Prat, Anna
    Rodriguez-Vida, Alejo
    Cardona, Laura
    Qin, Mengjuan
    Arpi-Llucia, Oriol
    Soria-Jimenez, Luis
    Menendez, Silvia
    Quimis, Fabricio Gerel
    Galindo, Miguel
    Arriola, Edurne
    Salido, Marta
    Juanpere-Rodero, Nuria
    Rojo, Federico
    Muntasell, Aura
    Albanell, Joan
    Rovira, Ana
    Bellmunt, Joaquim
    MOLECULAR ONCOLOGY, 2025, 19 (01) : 151 - 172
  • [24] Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies
    Philips, George K.
    Atkins, Michael
    INTERNATIONAL IMMUNOLOGY, 2015, 27 (01) : 39 - 46
  • [25] Anti-PD1 and anti-PD-L1 in the treatment of metastatic melanoma
    Simeone, Ester
    Grimaldi, Antonio M.
    Ascierto, Paolo A.
    MELANOMA MANAGEMENT, 2015, 2 (01) : 41 - 50
  • [26] Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy
    Yi, Bin
    Cheng, Hao
    Wyczechowska, Dorota
    Yu, Qingzhao
    Li Li
    Ochoa, Augusto C.
    Riker, Adam, I
    Xi, Yaguang
    MOLECULAR CANCER THERAPEUTICS, 2021, 20 (07) : 1295 - 1304
  • [27] Anti-PD-L1 Immunotherapy Enhances Radiation-induced Abscopal Response in Glioblastoma
    Ene, Chibawanye
    Kreuser, Shannon
    Jung, Miyeon
    Parney, Ian
    Crane, Courtney
    Holland, Eric
    JOURNAL OF NEUROSURGERY, 2019, 131 (01)
  • [28] Sulindac modulates the response of triple negative breast cancer to anti-PD-L1 immunotherapy
    Yi, Bin
    Ma, Ruixia
    Xi, Yaguang
    CANCER RESEARCH, 2024, 84 (06)
  • [29] Discovery of low-molecular weight anti-PD-L1 peptides for cancer immunotherapy
    Liu, Hao
    Zhao, Zhen
    Zhang, Li
    Li, Yuanke
    Jain, Akshay
    Barve, Ashutosh
    Jin, Wei
    Liu, Yanli
    Fetse, John
    Cheng, Kun
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [30] In the immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy modifying the sensitivity to conventional cancer therapies?
    Aspeslagh, Sandrine
    Matias, Margarida
    Palomar, Virginia
    Dercle, Laurent
    Lanoy, Emilie
    Soria, Jean-Charles
    Postel-Vinay, Sophie
    EUROPEAN JOURNAL OF CANCER, 2017, 87 : 65 - 74
12345